Adrián Alonso-Núñez
Research Subjects
Adrián Alonso-Núñez has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Rivera-Gallego
Internal Medicine Department, SERGAS-Hospital Alvaro Cunqueiro, 36312 Vigo, Spain
1 shared publication - Aurora Ruz-Zafra
Internal Medicine Department, Hospital de la Serranía, 29400 Ronda, Spain
1 shared publication - Beatriz San Millán
Servicio de Anatomía Patológica y Neuropatología; Complejo Hospitalario Universitario de Vigo (Meixoeiro); Vigo, Spain
1 shared publication Carlos Fernández-Pereira
Translational Neuroscience Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Área Sanitaria de Vigo-Hospital Álvaro Cunqueiro, SERGAS-UVIGO, CIBERSAM-ISCIII, Vigo, Spain
1 shared publication- Carlos Fernández-Pereira
Translational Research in Neurological Diseases Group (ITEN), Health Research Institute of Santiago de Compostela (IDIS), Santiago University Complex, SERGAS-USC, 15706 Santiago de Compostela, Spain
1 shared publication Cristina Fernández-González
Centro de Investigación Mariña da Universidade de Vigo (CIM-UVigo), Vigo, Spain
1 shared publication
Latest Publications
- Open Access
- 30 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 6024
Inflammatory and Cardiovascular Biomarkers to Monitor Fabry Disease Progression
Fabry disease is an invalidating multisystemic disorder affecting α-Galactosidase, a rate-limiting hydrolase dedicated to lipid catabolism. Non-metabolized substrates, such as Globotriaosylceramide and its derivatives trigger the direct or indirect activation of inflammatory events and endothelial dysfunction. In spite of the efficacy demonstrated by enzyme replacement therapy or pharmacological chaperones in delaying disease progression, few studies have analyzed whether these treatments can improve the pro-inflammatory state of FD patients. Therefore, the aim of this work was to assess cytokines and cardiovascular risk-related proteins detectable in plasma from FD patients, whether treated or not with ERT, to evaluate the reliability of these markers in monitoring disease stage and treatment effects. We identified inflammatory and endothelial dysfunction markers (ADAMTS-13, TNF-α, GDF-15, MIP-1β, VEGFA, MPO, and MIC-1) that cooperate in a common pathway and are increased in FD patients’ plasma samples. As shown by the assessment of these proteins over time, they can help to evaluate the risk of higher severity in FD, as well as ERT effects. Even though the analyzed proteins cannot be considered as proper biomarkers due to their non-specificity to FD, taken together they can provide a signature of reference molecules with prognostic value for early diagnosis, and evaluation of disease progression and treatment efficacy, using blood samples.
- 30 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 6024
Open AccessInflammatory and Cardiovascular Biomarkers to Monitor Fabry Disease Progression
Fabry disease is an invalidating multisystemic disorder affecting α-Galactosidase, a rate-limiting hydrolase dedicated to lipid catabolism. Non-metabolized substrates, such as Globotriaosylceramide and its derivatives trigger the direct or indirect activation of inflammatory events and endothelial dysfunction. In spite of the efficacy demonstrated by enzyme replacement therapy or pharmacological chaperones in delaying disease progression, few studies have analyzed whether these treatments can improve the pro-inflammatory state of FD patients. Therefore, the aim of this work was to assess cytokines and cardiovascular risk-related proteins detectable in plasma from FD patients, whether treated or not with ERT, to evaluate the reliability of these markers in monitoring disease stage and treatment effects. We identified inflammatory and endothelial dysfunction markers (ADAMTS-13, TNF-α, GDF-15, MIP-1β, VEGFA, MPO, and MIC-1) that cooperate in a common pathway and are increased in FD patients’ plasma samples. As shown by the assessment of these proteins over time, they can help to evaluate the risk of higher severity in FD, as well as ERT effects. Even though the analyzed proteins cannot be considered as proper biomarkers due to their non-specificity to FD, taken together they can provide a signature of reference molecules with prognostic value for early diagnosis, and evaluation of disease progression and treatment efficacy, using blood samples.
- Open Access
- 24 April 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1384198
Plasma IGFBP-3 and IGFBP-5 levels are decreased during acute manic episodes in bipolar disorder patients
Introduction: Bipolar disorder (BD) is a recurrent and disabling psychiatric disorder related to low-grade peripheral inflammation and altered levels of the members of the insulin-like growth factor (IGF) family. The aim of this study was to evaluate the plasma levels of IGF-2, insulin-like growth factor-binding protein 1 (IGFBP-1), IGFBP-3, IGFBP-5, IGFBP-7, and inflammatory markers such as tumor necrosis factor α (TNF-α), monocyte chemoattractant protein 1 (MCP-1), and macrophage inflammatory protein 1β (MIP-1β).Methods: We used the Young Mania Rating Scale (YMRS) to determine the severity of the symptomatology, while proteins were measured by enzyme-linked immunosorbent assay (ELISA). We included 20 patients with BD who suffered a manic episode and 20 controls. Some BD patients (n = 10) were evaluated after a period (17 ± 8 days) of pharmacological treatment.Results: No statistical difference was found in IGF-2, IGFBP-1, IGFBP-7, TNF-α, and MIP-1β levels. However, IGFBP-3 and IGFBP-5 levels were found to be statistically decreased in BD patients. Conversely, the MCP-1 level was significantly increased in BD patients, but their levels were normalized after treatment. Intriguingly, only IGFBP-1 levels were significantly decreased after treatment. No significant correlation was found between the YMRS and any of the proteins studied either before or after treatment or between IGF proteins and inflammatory markers.Discussion: To some extent, IGFBP-3 and IGFBP-5 might be further explored as potential indicators of treatment responsiveness or diagnosis biomarkers in BD.
- 24 April 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1384198
Open AccessPlasma IGFBP-3 and IGFBP-5 levels are decreased during acute manic episodes in bipolar disorder patients
Introduction: Bipolar disorder (BD) is a recurrent and disabling psychiatric disorder related to low-grade peripheral inflammation and altered levels of the members of the insulin-like growth factor (IGF) family. The aim of this study was to evaluate the plasma levels of IGF-2, insulin-like growth factor-binding protein 1 (IGFBP-1), IGFBP-3, IGFBP-5, IGFBP-7, and inflammatory markers such as tumor necrosis factor α (TNF-α), monocyte chemoattractant protein 1 (MCP-1), and macrophage inflammatory protein 1β (MIP-1β).Methods: We used the Young Mania Rating Scale (YMRS) to determine the severity of the symptomatology, while proteins were measured by enzyme-linked immunosorbent assay (ELISA). We included 20 patients with BD who suffered a manic episode and 20 controls. Some BD patients (n = 10) were evaluated after a period (17 ± 8 days) of pharmacological treatment.Results: No statistical difference was found in IGF-2, IGFBP-1, IGFBP-7, TNF-α, and MIP-1β levels. However, IGFBP-3 and IGFBP-5 levels were found to be statistically decreased in BD patients. Conversely, the MCP-1 level was significantly increased in BD patients, but their levels were normalized after treatment. Intriguingly, only IGFBP-1 levels were significantly decreased after treatment. No significant correlation was found between the YMRS and any of the proteins studied either before or after treatment or between IGF proteins and inflammatory markers.Discussion: To some extent, IGFBP-3 and IGFBP-5 might be further explored as potential indicators of treatment responsiveness or diagnosis biomarkers in BD.
- Open Access
- 9 April 2021
- Published by Frontiers Media SA in Frontiers in Marine Science
- Vol. 8
Temperature Fluctuation Attenuates the Effects of Warming in Estuarine Microbial Plankton Communities
Sea surface warming has the potential to alter the diversity, trophic organization and productivity of marine communities. However, it is unknown if temperature fluctuations that ecosystems naturally experience can alter the predicted impacts of warming. We address this uncertainty by exposing a natural marine plankton community to warming conditions (+3°C) under a constant vs. fluctuating (±3°C) temperature regime using an experimental mesocosm approach. We evaluated changes in stoichiometry, biomass, nutrient uptake, taxonomic composition, species richness and diversity, photosynthetic performance, and community metabolic balance. Overall, warming had a stronger impact than fluctuating temperature on all biological organization levels considered. As the ecological succession progressed toward post-bloom, the effects of warming on phytoplankton biomass, species richness, and net community productivity intensified, likely due to a stimulated microzooplankton grazing, and the community metabolic balance shifted toward a CO2 source. However, fluctuating temperatures reduced the negative effects of warming on photosynthetic performance and net community productivity by 40%. Our results demonstrate that temperature fluctuations may temper the negative effect of warming on marine net productivity. These findings highlight the need to consider short-term thermal fluctuations in experimental and modeling approaches because the use of constant warming conditions could lead to an overestimation of the real magnitude of climate change impacts on marine ecosystems.
- 9 April 2021
- Published by Frontiers Media SA in Frontiers in Marine Science
- Vol. 8
Open AccessTemperature Fluctuation Attenuates the Effects of Warming in Estuarine Microbial Plankton Communities
Sea surface warming has the potential to alter the diversity, trophic organization and productivity of marine communities. However, it is unknown if temperature fluctuations that ecosystems naturally experience can alter the predicted impacts of warming. We address this uncertainty by exposing a natural marine plankton community to warming conditions (+3°C) under a constant vs. fluctuating (±3°C) temperature regime using an experimental mesocosm approach. We evaluated changes in stoichiometry, biomass, nutrient uptake, taxonomic composition, species richness and diversity, photosynthetic performance, and community metabolic balance. Overall, warming had a stronger impact than fluctuating temperature on all biological organization levels considered. As the ecological succession progressed toward post-bloom, the effects of warming on phytoplankton biomass, species richness, and net community productivity intensified, likely due to a stimulated microzooplankton grazing, and the community metabolic balance shifted toward a CO2 source. However, fluctuating temperatures reduced the negative effects of warming on photosynthetic performance and net community productivity by 40%. Our results demonstrate that temperature fluctuations may temper the negative effect of warming on marine net productivity. These findings highlight the need to consider short-term thermal fluctuations in experimental and modeling approaches because the use of constant warming conditions could lead to an overestimation of the real magnitude of climate change impacts on marine ecosystems.